Myeloperoxidase, Malondialdehyde and serum Lipids in type 2 diabetes mellitus

Begum, Mohamedi; Kumar, JS; D'Souza, Hilda Priya; Sushith, Sushith; B, Prathima M.; Reshma, S; M.D, Shashikala; Anil, Manjula; Nair, Suriyan S.; Kumar, Kavitha Ashok

doi:10.5455/jib.20150331115356

Cited by 6 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consistent with our study, several clinical parameters and indices were elevated in pre-DM/ T2DM patients compared with normoglycemic nondiabetic individuals in other studies, implying an increased risk for cardiovascular events. [21][22][23] Our findings confirm a significant difference in MPO levels in nondiabetic MetS patients compared with normoglycemic individuals (p = 0.026), which is supported by the study conducted by Fonseca and colleagues. 24 Nevertheless, in our study this was not the case regarding the pre-DM/T2DM MetS group compared with the control group, as no significant variation was detected.…”

Section: Discussionsupporting

confidence: 89%

Cross-sectional correlates of myeloperoxidase and alpha-1-acid glycoprotein with adiposity, atherogenic and hematological indices in metabolic syndrome patients with or without diabetes

Alquoqa

Kasabri

Naffa

et al. 2018

Therapeutic Advances in Endocrinology

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 89%

Cross-sectional correlates of myeloperoxidase and alpha-1-acid glycoprotein with adiposity, atherogenic and hematological indices in metabolic syndrome patients with or without diabetes

Alquoqa

Kasabri

Naffa

et al. 2018

Therapeutic Advances in Endocrinology

View full text Add to dashboard Cite

show abstract

“…In addition, type 1 diabetic patients have 10-fold higher risk of cardiovascular mortality in comparison to general population (Lind et al 2014). AIP is a critical marker for predicting CVD risk, because of the strong association between AIP and atherosclerosis (Begum et al 2015).…”

Section: Introductionmentioning

confidence: 99%

Assessment the effects of insulin on adiponectin, nitric oxide, myeloperoxidase and lipid profile in type 1 diabetic patients

Mohammad¹,

Fathi²,

Allwash³

2021

PHAR

View full text Add to dashboard Cite

Type 1 diabetes (T1DM) is well recognized risk factor cardiovascular disease (CVD). Insulin therapy is recommended for all patients with type 1 diabetes. Previous findings showed that diabetes impairs endothelial function and increased glucose level reduces nitric oxide (NO) output and increases myeloperoxidase (MPO) activity. However, adiponectin (APN) decreases serum glucose levels. The current study evaluated effects of insulin therapy on circulating levels of oxidative stress and CVD biomarkers like NO, APN, MPO, AIP and lipid profile in type 1 diabetic patients. Fifty patients with T1DM and 18 healthy people were enrolled in this study. The recruited people with T1DM were classified into two groups: 22 newly diagnosed (untreated) type 1 diabetic patients and 28 insulin treated patients. In all groups, circulating NO, APN, MPO, AIP and lipids levels were measured. Compared to control, untreated diabetes revealed a significant increase in the serum levels of APN, MPO, TG, VLDL, TC, LDL and AIP, with a marked reduction in NO and HDL levels. However, insulin therapy significantly lowered MPO, TC and LDL, with no significant changes in the other biochemical parameters. As expected, oxidative stress and CVD-associated markers were significantly increased in untreated diabetes. Insulin therapy exhibited a relatively positive effect on oxidative stress and CVD biomarkers. Accordingly, insulin plus antioxidant supplementation required to normalize these parameters.

show abstract

Increased malondialdehyde vs. reduced sirtuin 1 in relation with adiposity, atherogenicity and hematological indices in metabolic syndrome patients with and without prediabetes

Rkhaya

Bulatova

Kasabri

et al. 2018

Diabetes & Metabolic Syndrome: Clinical Research & Revi

View full text Add to dashboard Cite

Myeloperoxidase, Malondialdehyde and serum Lipids in type 2 diabetes mellitus

Cited by 6 publications

References 0 publications

Cross-sectional correlates of myeloperoxidase and alpha-1-acid glycoprotein with adiposity, atherogenic and hematological indices in metabolic syndrome patients with or without diabetes

Cross-sectional correlates of myeloperoxidase and alpha-1-acid glycoprotein with adiposity, atherogenic and hematological indices in metabolic syndrome patients with or without diabetes

Assessment the effects of insulin on adiponectin, nitric oxide, myeloperoxidase and lipid profile in type 1 diabetic patients

Increased malondialdehyde vs. reduced sirtuin 1 in relation with adiposity, atherogenicity and hematological indices in metabolic syndrome patients with and without prediabetes

Contact Info

Product

Resources

About